Secondary Hyperparathyroidism Clinical Trial
— CaT50HDOfficial title:
The Effect of Increasing Dialysate Calcium on Serum Calcification Propensity in Subjects With Secondary Hyperparathyroidism and End-Stage Kidney Disease
Patients with end-stage kidney disease (ESKD) have an increased risk of cardiovascular mortality. High parathyroid hormone (PTH) from secondary hyperparathyroidism leads to increased efflux of phosphate and calcium from bone, which exacerbates vascular calcification and increases the risk of bone fractures. The main driving factor for secondary hyperparathyroidism is hypocalcaemia caused by low levels of 1,25-dihydroxy vitamin D and pharmacological supplementation with activated vitamin D and oral calcium-containing phosphate-binders are used to control secondary hyperparathyroidism. The amount of calcium used in this context is controversial, as higher calcium load in blood may theoretically increase vascular calcification. Conversely, by alleviating the efflux of phosphate and calcium from bone due to secondary hyperparathyroidism, increasing the load of calcium might actually prevent vascular calcification. To study this further, we wish to conduct a randomised double-blinded controlled clinical trial of increasing dialysate Ca from 1.25 mmol/L (standard dialysate concentration) to 1.50 mmol/L in patients with ESKD and secondary hyperparathyroidism on maintenance haemodialysis (HD). The overall effect of increased dialysate calcium will be gauged by its effect on serum calcification propensity (T50) and on markers of bone turnover.
Status | Not yet recruiting |
Enrollment | 48 |
Est. completion date | August 1, 2025 |
Est. primary completion date | August 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age = 18 years. - Treatment with thrice-weekly maintenance HD for ESKD for > 3 months. - Dialysate calcium of 1.25 mmol/L (standard concentration). - Plasma ionised calcium < 1.35 mmol/L (average of last 3 months). - Plasma intact PTH > 14 ?mol/L. - Plasma total alkaline phosphatase >90 U/L - Negative pregnancy test and use of highly effective and safe contraception. - Able to give written informed consent. Exclusion Criteria: - Treatment with peritoneal dialysis. - Clinical bone fracture within the last 6 months. - Treatment with bisphosphonates, denosumab, romosozumab, or teriparatide within the last 3 months. - Other diseases or conditions, which, in the opinion of the site investigator, would prevent participation in or completion of the trial. - Pregnancy or breastfeeding. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Iain Bressendorff |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Difference in serum calcification propensity (T50) | Between-groups difference in T50 at day 28 adjusted for T50 at day 0 | 28 days | |
Secondary | Difference in bone-specific alkaline phosphatase (bALP) | Between-groups difference in bALP at day 28 adjusted for bALP at day 0 | 28 days | |
Secondary | Difference in procollagen 1 intact N-terminal propeptide (P1NP) | Between-groups difference in P1NP at day 28 adjusted for P1NP at day 0 | 28 days | |
Secondary | Difference in tartrate-resistant acid phosphatase 5b (TRAcP 5b) | Between-groups difference in TRAcP 5b at day 28 adjusted for TRAcP 5b at day 0 | 28 days | |
Secondary | Difference in parathyroid hormone (PTH) | Between-groups difference in PTH at day 28 adjusted for PTH at day 0 | 28 days | |
Secondary | Difference in calciprotein monomers (CPM) | Between-groups difference in CPM at day 28 adjusted for CPM at day 0 | 28 days | |
Secondary | Difference in primary calciprotein particles (CPP-1) | Between-groups difference in CPP-1 at day 28 adjusted for CPP-1 at day 0 | 28 days | |
Secondary | Difference in primary calciprotein particles (CPP-2) | Between-groups difference in CPP-2 at day 28 adjusted for CPP-2 at day 0 | 28 days | |
Secondary | Difference in plasma ionised calcium (iCa) | Between-groups difference in iCa at day 28 adjusted for iCa at day 0 | 28 days | |
Secondary | Difference in plasma phosphate (PO4) | Between-groups difference in PO4 at day 28 adjusted for PO4 at day 0 | 28 days | |
Secondary | Difference in plasma magnesium (Mg) | Between-groups difference in Mg at day 28 adjusted for Mg at day 0 | 28 days | |
Secondary | Difference in all above variables | Within-groups difference in all above variables at day 28 adjusted for values at day 0 | 28 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02549417 -
Phase 3 Study of KHK7580
|
Phase 3 | |
Completed |
NCT02549404 -
Phase 3 Study of KHK7580
|
Phase 3 | |
Not yet recruiting |
NCT02536287 -
Comparison of Total Parathyroidectomy With and Without Autotransplantation
|
Phase 3 | |
Completed |
NCT02549391 -
Phase 3 Study of KHK7580
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03023748 -
Intravenous Paricalcitol in Chronic Hemodialysis Patients
|
Phase 4 | |
Withdrawn |
NCT01426724 -
Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease
|
N/A | |
Completed |
NCT01101113 -
Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level
|
Phase 4 | |
Completed |
NCT01220050 -
Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism
|
Phase 2 | |
Completed |
NCT00537979 -
Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis
|
Phase 4 | |
Completed |
NCT00379899 -
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
|
Phase 4 | |
Completed |
NCT00431496 -
A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD)
|
Phase 4 | |
Completed |
NCT00117052 -
SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism
|
Phase 3 | |
Completed |
NCT00073710 -
Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium
|
Phase 4 | |
Completed |
NCT03626948 -
SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis
|
Phase 3 | |
Completed |
NCT01382212 -
A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis
|
Phase 3 | |
Completed |
NCT01219855 -
Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)
|
Phase 2/Phase 3 | |
Completed |
NCT01224782 -
Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT)
|
N/A | |
Completed |
NCT00990704 -
Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism
|
Phase 2 | |
Completed |
NCT00999037 -
FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease
|
N/A | |
Completed |
NCT00742716 -
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
|
Phase 2 |